Breast Cancer: Role of Early Detection, Treatment and Prevention

乳腺癌：早期检测、治疗和预防的作用

• 批准号: 7277143
• 负责人: Sandra J Lee
• 金额: $ 24.62万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7277143
• 关键词: African; African American; Age; Age at First Live Birth; American; BRCA1 gene; BRCA2 gene; Biopsy; Breast Cancer Model; Diagnosis; Early Diagnosis; Elderly; Family history of; General Population; Internet; Invasive; Investigation; Modeling; Noninfiltrating Intraductal Carcinoma; Numbers; Pharmaceutical Preparations; Physicians; Population; Prevention; Preventive; Rate; Recommendation; Recording of previous events; Research; Research Personnel; Risk; Role; Schedule; Screening procedure; Site; Source; Tamoxifen; Uninsured; United States; Woman; malignant breast neoplasm; mortality; parity; programs

DESCRIPTION (provided by applicant): It is planned to apply the stochastic model developed earlier to breast cancer issues associated with the U.S. population. Among the issues which will be studied are: estimating the U.S. breast cancer mortality for the period 2005-2020; investigate mortality for sub-populations; e.g. African-American, uninsured population and various scenarios; continue investigations of optimal screening schedules; investigate the role of the underreporting in SEER of invasive breast cancer following DCIS; investigate the influence on mortality if the number of women taking tamoxifen or reloxifene as a preventive agent is increased; develop a public web site (a) which will allow investigators to make use of our theoretical breast cancer model and (b) to communicate to the general public the breast cancer predicted mortality and false positive rate for any screening program.

描述（由申请人提供）： 计划将早期开发的随机模型应用于与美国人口相关的乳腺癌问题。将研究的问题包括：估计 2005 年至 2020 年期间美国乳腺癌死亡率；调查亚人群的死亡率；例如非裔美国人、未参保人群和各种情景；继续研究最佳筛查时间表；调查 DCIS 后浸润性乳腺癌 SEER 漏报的作用；调查服用他莫昔芬或瑞洛昔芬作为预防药物的妇女人数增加对死亡率的影响；开发一个公共网站 (a) 允许研究人员利用我们的乳腺癌理论模型，以及 (b) 向公众传达乳腺癌预测死亡率和任何筛查计划的假阳性率。